Get the Stockscreener App
7.98
8.06%
-0.70
After Hours:
7.99
0.010
+0.13%
Immix Biopharma Inc stock is traded at $7.98, with a volume of 1.47M.
It is down -8.06% in the last 24 hours and down -33.05% over the past month.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
See More
Previous Close:
$8.68
Open:
$8.67
24h Volume:
1.47M
Relative Volume:
1.12
Market Cap:
$661.57M
Revenue:
Net Income/Loss:
$-34.98M
P/E Ratio:
-8.6749
EPS:
-0.9199
Net Cash Flow:
$-32.77M
1W Performance:
-15.64%
1M Performance:
-33.05%
6M Performance:
-19.88%
1Y Performance:
+195.56%
1-Day Range:
$7.95
$8.67
1-Week Range:
$7.95
$9.56
52-Week Range:
$2.61
$15.10
Immix Biopharma Inc Stock (IMMX) Company Profile
Name
Immix Biopharma Inc
Sector
Industry
Phone
(888) 958-1084
Address
11400 WEST OLYMPIC BLVD., LOS ANGELES
Compare IMMX vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMMX
Immix Biopharma Inc
|
7.98 | 661.57M | 0 | -34.98M | -32.77M | -0.9199 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Immix Biopharma Inc Stock (IMMX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-22-26 | Initiated | Needham | Buy |
| Jun-18-26 | Initiated | BofA Securities | Buy |
| Mar-25-26 | Initiated | Morgan Stanley | Overweight |
| Mar-09-26 | Initiated | Citizens | Mkt Outperform |
| Feb-09-26 | Initiated | Mizuho | Outperform |
Immix Biopharma Inc Stock (IMMX) Latest News
Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference - Yahoo Finance
Immix Biopharma to Participate in the 45th Annual J.P.... - t.co
San Francisco will host Immix Biopharma’s presentation Jan. 11–14. - Stock Titan
Immix Biopharma Prices $125 Million Equity Offering - The Globe and Mail
Immix Biopharma Announces Closing Of $125 Million Underwritten Offering Of Common Stock - TradingView
Immix Biopharma closes $117.1m stock offering By Investing.com - Investing.com Nigeria
Immix Biopharma Closes $117.1 Million Underwritten Registered Offering - Quiver Quantitative
Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock - GlobeNewswire
Immix plans to use about $117 million for treatment development and company operations - Stock Titan
Immunome (IMNM) Is Down 6.5% After FDA Clears IND For Novel ADC IM-1340 Trial – Has The Bull Case Changed? - Yahoo Finance
Immix Biopharma Reports 89% Complete Response Rate in Phase 2 NXC-201 Trial - Yahoo Finance
Immix Biopharma prices $125M stock offering at $11 per share - Investing.com Nigeria
Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock - GlobeNewswire
All 25 new patients had a complete response or tested negative for remaining disease - Stock Titan
IMMXAL Amyloidosis CAR T Platform And Regulatory Tailwinds Will Drive Long-Term Opportunity - Simply Wall Street
Immix Biopharma (Nasdaq:IMMX)Stock Analysis - Simply Wall Street
Immix Biopharma (NasdaqCM:IMMX) Stock Price - Simply Wall Street
Immix Biopharma (IMMX) Holds at $13.77: Biotech Stock Navigates Tight Trading RangeBeta Neutral Pair - dars.gov.et
Immix Biopharma (IMMX) Holds at $13.77: Biotech Stock Navigates Tight Trading RangeSign of Strength - dars.gov.et
Immix Biopharma (IMMX) Holds at $13.77: Biotech Stock Navigates Tight Trading RangeIndex Put Call - siam.in
Immix (IMMX) Today: Moves 1.32% Lower to $13.48 at the Close; Chart Watch: the Price Remains Bounded by the Supplied Support and Resistance in the Available RecordUp Down Volume - vinanet.vn
Tocqueville Asset Management L.P. Buys New Position in Immix Biopharma, Inc. $IMMX - MarketBeat
Blue Owl Capital Holdings LP Makes New $4.51 Million Investment in Immix Biopharma, Inc. $IMMX - MarketBeat
Immix (IMMX) Quarterly Scorecard: The Available Figures Are Largely in Line on the Day; Session Move: Shares Fall 1.21% in the Current UpdatePre-Earnings Setup - vinanet.vn
Immix Biopharma (NASDAQ:IMMX) Sets New 12-Month HighStill a Buy? - MarketBeat
Analysts Offer Insights on Healthcare Companies: AEON Biopharma (AEON) and Immix Biopharma (IMMX) - The Globe and Mail
Immix Biopharma Stock Price Forecast. Should You Buy IMMX? - StockInvest.us
Immix Biopharma (NASDAQ:IMMX) Stock Price Down 4.5%Here's Why - MarketBeat
Immix Biopharma (IMMX) gains 5.6% stake holder led by Eventide Asset Management - Stock Titan
Citizens reiterates Immix Biopharma stock rating on pipeline progress By Investing.com - Investing.com Australia
Citizens reiterates Immix Biopharma stock rating on pipeline progress - Investing.com
Citizens reiterates Immix Biopharma stock rating on pipeline progress By Investing.com - Investing.com Canada
Citizens reiterates Immix Biopharma stock rating on pipeline progress By Investing.com - Investing.com India
Citizens reiterates Immix Biopharma stock rating on pipeline progress By Investing.com - Investing.com UK
Citizens reiterates Immix Biopharma stock rating on pipeline progress - Investing.com
Janus Henderson Group (IMMX) discloses 9.78M-share beneficial stake in Immix Biopharma - Stock Titan
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc.IMMX - PR Newswire
Immix Biopharma Q3 EPS Estimate Lowered by HC Wainwright - MarketBeat
Immix Biopharma (NASDAQ:IMMX) Trading 7.1% HigherStill a Buy? - MarketBeat
HC Wainwright Estimates Immix Biopharma FY2027 Earnings - MarketBeat
Immix Biopharma publishes corporate presentation on NXC-201 BCMA CAR-T in relapsed/refractory AL amyloidosis - Bitget
Immix Biopharma, Inc. Stock 12‑Month Price Target Cut to $20.44, Implies 102% Upside - TradingView
Morgan Stanley Adjusts PT on Immix Biopharma to $19 From $20, Maintains Overweight Rating - marketscreener.com
Morgan Stanley Adjusts PT on Immix Biopharma to $19 From $20, Maintains Overweight Rating - Moomoo
IMMIX BIOPHARMA, INC. : H.C. WAINWRIGHT RAISES TARGET PRICE TO $25 FROM $20 - Bitget
H.C. Wainwright raises Immix Biopharma price target to $25 By Investing.com - Investing.com Australia
H.C. Wainwright raises Immix Biopharma price target to $25 By Investing.com - Investing.com South Africa
H.C. Wainwright raises Immix Biopharma price target to $25 By Investing.com - Investing.com Nigeria
H.C. Wainwright raises Immix Biopharma price target to $25 - Investing.com India
H.C. Wainwright raises Immix Biopharma price target to $25 - Investing.com
Immix Biopharma Inc Stock (IMMX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Immix Biopharma Inc Stock (IMMX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Morris Gabriel S | CFO |
Dec 10 '25 |
Buy |
6.58 |
770 |
5,067 |
291,429 |
2.80%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):